South Wales, Sept. 17 -- United Kingdom Intellectual Property Office (UKIPO) has registered trademark "ALTHEOME" on Aug. 22. The details about the trademark application no. UK00004253298 published in the journal no. 2025/036 (Sept. 5).
With Forresters IP LLP as representative, Emles Labs Limited filed the trademark application for the below mentioned good(s)/service(s).
Class 42 : Biotechnological research services; scientific research services; laboratory research services; laboratory testing services; design and product development services; scientific analysis services; biological research services; medical research services; research and development services; clinic trial services; DNA sequencing for medical research and technology research purposes; biotechnological research services, scientific research services, laboratory research services, laboratory testing services, design and product development services, scientific analysis services, biological research services, medical research services, research and development services, clinic trial services, and DNA sequencing for medical research and technology research purposes, all relating to proteomics, proteomics profiling services, quantitative and qualitative protein analysis services, biomarker discovery, biomarker development, biomarker analysis, biomarker assays, discovery and development of biomarker assays, running samples for biomarkers across proteomics and genomics, genomic sequencing, the analysis of protein biomarkers, microbiome analysis, multigenomics, structural and functional analysis of genomes, disease diagnosis, treatment monitoring and disease risk assessment; biotechnological research services, scientific research services, laboratory research services, laboratory testing services, design and product development services, scientific analysis services, biological research services, medical research services, research and development services, clinic trial services, and DNA sequencing for medical research and technology research purposes, all relating to testing for viruses, bacteria, parasites, yeast and antimicrobial resistance genes in areas including respiratory, blood culture identification, gastrointestinal, meningitis, encephalitis, pneumonia and joint infection; biotechnological research services, scientific research services, laboratory research services, laboratory testing services, design and product development services, scientific analysis services, biological research services, medical research services, research and development services, clinic trial services, and DNA sequencing for medical research and technology research purposes, all relating to testing across respiratory infection, GI infection, STIs, vaginitis, meningitis, healthcare associated infection, COVID, tuberculosis, human papilloma infection, single nucleotide polymorphism, vector-borne disease, streptococcal infection, monkeypox, dermatophyte, urinary tract infection; design and development of diagnostic assays, devices, and platforms; bioinformatic services; biostatistics services; data and database services; data and database services, namely data analysis, data management, data hosting services, database development and maintenance, integration of data, data interpretation services, and curation and maintenance databases; computer modelling and computer simulation services; cloud computing services; design and development artificial intelligence and machine learning models; bioinformatic services, biostatistics services, data and database services, data and database services, namely data analysis, data management, data hosting services, database development and maintenance, integration of data, data interpretation services, and curation and maintenance databases, computer modelling and computer simulation services, cloud computing services, design and development artificial intelligence and machine learning models, all relating to proteomics, proteomics profiling services, quantitative and qualitative protein analysis services, biomarker discovery, biomarker development, biomarker analysis, biomarker assays, discovery and development of biomarker assays, running samples for biomarkers across proteomics and genomics, genomic sequencing, the analysis of protein biomarkers, microbiome analysis, multigenomics, structural and functional analysis of genomes, disease diagnosis, treatment monitoring and disease risk assessment; bioinformatic services, biostatistics services, data and database services, data and database services, namely data analysis, data management, data hosting services, database development and maintenance, integration of data, data interpretation services, and curation and maintenance databases, computer modelling and computer simulation services, cloud computing services, design and development artificial intelligence and machine learning models, all relating to testing for viruses, bacteria, parasites, yeast and antimicrobial resistance genes in areas including respiratory, blood culture identification, gastrointestinal, meningitis, encephalitis, pneumonia and joint infection; bioinformatic services, biostatistics services, data and database services, data and database services, namely data analysis, data management, data hosting services, database development and maintenance, integration of data, data interpretation services, and curation and maintenance databases, computer modelling and computer simulation services, cloud computing services, design and development artificial intelligence and machine learning models, all relating to testing across respiratory infection, GI infection, STIs, vaginitis, meningitis, healthcare associated infection, COVID, tuberculosis, human papilloma infection, single nucleotide polymorphism, vector-borne disease, streptococcal infection, monkeypox, dermatophyte, urinary tract infection; information, advisory and consultancy services relating to the aforesaid.
Class 44 : Pathological testing for diagnostic and treatment purposes; medical testing and analysis services relating to the diagnosis and treatment of disease; laboratory analysis services relating to the diagnosis and treatment of persons; pathological testing for diagnostic and treatment purposes, medical testing and analysis services relating to the diagnosis and treatment of disease, and laboratory analysis services relating to the diagnosis and treatment of persons, all relating to proteomics, proteomics profiling services, proteomics profiling services, quantitative and qualitative protein analysis services, biomarker discovery, biomarker development, biomarker analysis, biomarker assays, discovery and development of biomarker assays, running samples for biomarkers across proteomics and genomics, genomic sequencing, the analysis of protein biomarkers, microbiome analysis, multigenomics, structural and functional analysis of genomes, disease diagnosis, treatment monitoring and disease risk assessment; pathological testing for diagnostic and treatment purposes, medical testing and analysis services relating to the diagnosis and treatment of disease, and laboratory analysis services relating to the diagnosis and treatment of persons, all relating to testing for viruses, bacteria, parasites, yeast and antimicrobial resistance genes in areas including respiratory, blood culture identification, gastrointestinal, meningitis, encephalitis, pneumonia and joint infection; pathological testing for diagnostic and treatment purposes, medical testing and analysis services relating, all relating to testing across respiratory infection, GI infection, STIs, vaginitis, meningitis, healthcare associated infection, COVID, tuberculosis, human papilloma infection, single nucleotide polymorphism, vector-borne disease, streptococcal infection, monkeypox, dermatophyte, urinary tract infection; medical services; medial testing services; medical diagnostic services; medical analysis services; medical screening services; medical services, medial testing services, medical diagnostic services, medical analysis services, medical screening services, all relating to proteomics, proteomics profiling services, proteomics profiling services, quantitative and qualitative protein analysis services, biomarker discovery, biomarker development, biomarker analysis, biomarker assays, discovery and development of biomarker assays, running samples for biomarkers across proteomics and genomics, genomic sequencing, the analysis of protein biomarkers, microbiome analysis, multigenomics, structural and functional analysis of genomes, disease diagnosis, treatment monitoring and disease risk assessment; medical services, medial testing services, medical diagnostic services, medical analysis services, medical screening services, all relating to testing for viruses, bacteria, parasites, yeast and antimicrobial resistance genes in areas including respiratory, blood culture identification, gastrointestinal, meningitis, encephalitis, pneumonia and joint infection; medical services, medial testing services, medical diagnostic services, medical analysis services, medical screening services, all relating to testing across respiratory infection, GI infection, STIs, vaginitis, meningitis, healthcare associated infection, COVID, tuberculosis, human papilloma infection, single nucleotide polymorphism, vector-borne disease, streptococcal infection, monkeypox, dermatophyte, urinary tract infection; information, advisory and consultancy services relating to the aforesaid.
The original document can be viewed at: http://www.ipo.gov.uk/cgi-bin/redirect.cgi?type=tmj&link=6¶m1=UK00004253298
Disclaimer: Curated by HT Syndication.
